CN101568330A - 用于制备纳米粒形式的生物活性化合物的方法 - Google Patents

用于制备纳米粒形式的生物活性化合物的方法 Download PDF

Info

Publication number
CN101568330A
CN101568330A CNA2007800248024A CN200780024802A CN101568330A CN 101568330 A CN101568330 A CN 101568330A CN A2007800248024 A CNA2007800248024 A CN A2007800248024A CN 200780024802 A CN200780024802 A CN 200780024802A CN 101568330 A CN101568330 A CN 101568330A
Authority
CN
China
Prior art keywords
agent
grinding
nanoparticle
bioactive compound
grinding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800248024A
Other languages
English (en)
Chinese (zh)
Inventor
费利克斯·迈泽尔
拉法埃莱·卡马拉诺
弗兰克·卡鲁索
阿尔马·波斯特马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iceutica Pty Ltd
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006903527A external-priority patent/AU2006903527A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Priority to CN201210401138.3A priority Critical patent/CN102895194B/zh
Priority to CN201410460941.3A priority patent/CN104288103B/zh
Publication of CN101568330A publication Critical patent/CN101568330A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CNA2007800248024A 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法 Pending CN101568330A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201210401138.3A CN102895194B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法
CN201410460941.3A CN104288103B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006903527A AU2006903527A0 (en) 2006-06-30 Methods For The Preparation Of Pharmaceutically Active Compounds in Nanoparticulate Form
AU2006903527 2006-06-30
US60/915,955 2007-05-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201210401138.3A Division CN102895194B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法
CN201410460941.3A Division CN104288103B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法

Publications (1)

Publication Number Publication Date
CN101568330A true CN101568330A (zh) 2009-10-28

Family

ID=41284114

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201210401138.3A Expired - Fee Related CN102895194B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法
CNA2007800248024A Pending CN101568330A (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法
CN201410460941.3A Expired - Fee Related CN104288103B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201210401138.3A Expired - Fee Related CN102895194B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410460941.3A Expired - Fee Related CN104288103B (zh) 2006-06-30 2007-06-29 用于制备纳米粒形式的生物活性化合物的方法

Country Status (6)

Country Link
US (1) US8808751B2 (xx)
CN (3) CN102895194B (xx)
BR (1) BRPI0713053A2 (xx)
NZ (4) NZ599069A (xx)
TW (2) TWI564033B (xx)
ZA (1) ZA200810741B (xx)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104957360A (zh) * 2014-02-27 2015-10-07 巴罗顿-S.F.株式会社 非特异性免疫增强剂组合物、其制备方法及其应用
CN105246598A (zh) * 2013-03-15 2016-01-13 艾塞尤提卡公司 乙酸阿比特龙酯制剂
CN107281163A (zh) * 2017-07-05 2017-10-24 郑州大学 羧基化合物在促进载药纳米粒微球口服吸收方面的应用
US10292990B2 (en) 2013-09-27 2019-05-21 Sun Pharma Global Fze Abiraterone steroid formulation
CN110170489A (zh) * 2019-05-31 2019-08-27 国网河南省电力公司新野县供电公司 一种高压配电柜带电清洗装置和方法
CN110891549A (zh) * 2017-04-07 2020-03-17 玛亚实验室公司 改善治疗剂的溶解度和生物利用度的方法
WO2020113812A1 (zh) * 2018-12-03 2020-06-11 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用
CN111481514A (zh) * 2019-01-25 2020-08-04 鲁南制药集团股份有限公司 一种治疗高血脂的片剂及其制备方法
WO2020173364A1 (zh) * 2019-02-27 2020-09-03 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2960377A1 (en) 2006-06-30 2008-01-03 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP6141013B2 (ja) * 2009-04-24 2017-06-07 イシューティカ ピーティーワイ リミテッド 商業的規模での封入ナノ粒子の製造
KR101679522B1 (ko) * 2009-04-24 2016-11-24 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법
CA2759125C (en) 2009-04-24 2017-08-15 Iceutica Pty Ltd A novel formulation of indomethacin
EA201171279A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Производство инкапсулированных наночастиц с высокой объемной долей
MY168079A (en) 2009-04-24 2018-10-11 Iceutica Pty Ltd A novel formulation of diclofenac
FR2953217B1 (fr) * 2009-11-27 2012-10-05 Ifremer Procede de depolymerisation de polysaccharides par broyage mecanique
US8740114B2 (en) 2010-01-07 2014-06-03 Metronic Xomed, Inc. System and method of bone processing
US8465582B2 (en) * 2010-03-16 2013-06-18 Taipei Medical University Process for producing inorganic interconnected 3D open cell bone substitutes
WO2012158380A1 (en) 2011-05-16 2012-11-22 Drexel University Disaggregation of aggregated nanodiamond clusters
TWI580442B (zh) * 2011-10-19 2017-05-01 傑特大學 醫藥毫微懸浮物
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN111939151A (zh) * 2020-07-04 2020-11-17 浙江工业大学 一种复合型阿霉素白蛋白纳米粒及其制备方法和应用
CN114088624B (zh) * 2021-11-09 2022-08-26 北京中检葆泰生物技术有限公司 用于谷物颗粒表面规则度检测设备
CN114166871B (zh) * 2022-02-15 2022-04-26 西南石油大学 一种陆相页岩油储层脆性评价方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
ES2303527T3 (es) * 2000-05-10 2008-08-16 Jagotec Ag Procedimiento de molienda.
JP4969761B2 (ja) * 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
EP1443912B1 (en) * 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003297151A1 (en) * 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP6091041B2 (ja) * 2004-12-31 2017-03-08 イシューティカ ピーティーワイ リミテッド ナノ粒子組成物及びその合成方法
WO2007070851A2 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105246598A (zh) * 2013-03-15 2016-01-13 艾塞尤提卡公司 乙酸阿比特龙酯制剂
CN105246598B (zh) * 2013-03-15 2019-09-13 太阳药业环球公司 乙酸阿比特龙酯制剂
US10292990B2 (en) 2013-09-27 2019-05-21 Sun Pharma Global Fze Abiraterone steroid formulation
CN104957360A (zh) * 2014-02-27 2015-10-07 巴罗顿-S.F.株式会社 非特异性免疫增强剂组合物、其制备方法及其应用
CN104957360B (zh) * 2014-02-27 2019-03-12 巴罗顿- S.F.株式会社 非特异性免疫增强剂组合物、其制备方法及其应用
CN110891549A (zh) * 2017-04-07 2020-03-17 玛亚实验室公司 改善治疗剂的溶解度和生物利用度的方法
CN107281163A (zh) * 2017-07-05 2017-10-24 郑州大学 羧基化合物在促进载药纳米粒微球口服吸收方面的应用
CN107281163B (zh) * 2017-07-05 2020-08-14 郑州大学 羧基化合物在促进载药纳米粒微球口服吸收方面的应用
WO2020113812A1 (zh) * 2018-12-03 2020-06-11 泓博元生命科技（深圳）有限公司 含nadh的生物高分子纳米球及其制备方法与应用
CN111481514A (zh) * 2019-01-25 2020-08-04 鲁南制药集团股份有限公司 一种治疗高血脂的片剂及其制备方法
CN111481514B (zh) * 2019-01-25 2023-01-10 鲁南制药集团股份有限公司 一种治疗高血脂的片剂及其制备方法
WO2020173364A1 (zh) * 2019-02-27 2020-09-03 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
CN113508114A (zh) * 2019-02-27 2021-10-15 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
CN110170489A (zh) * 2019-05-31 2019-08-27 国网河南省电力公司新野县供电公司 一种高压配电柜带电清洗装置和方法
CN110170489B (zh) * 2019-05-31 2021-06-01 国网河南省电力公司新野县供电公司 一种高压配电柜带电清洗装置和方法

Also Published As

Publication number Publication date
TW201609190A (zh) 2016-03-16
CN104288103A (zh) 2015-01-21
ZA200810741B (en) 2010-05-26
NZ614995A (en) 2015-03-27
BRPI0713053A2 (pt) 2012-07-17
TWI564033B (zh) 2017-01-01
NZ573823A (en) 2012-05-25
TW200808377A (en) 2008-02-16
NZ705763A (en) 2016-10-28
TWI645862B (zh) 2019-01-01
CN102895194B (zh) 2015-09-09
CN104288103B (zh) 2019-10-15
CN102895194A (zh) 2013-01-30
NZ599069A (en) 2013-10-25
US8808751B2 (en) 2014-08-19
US20100092563A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CN102895194B (zh) 用于制备纳米粒形式的生物活性化合物的方法
JP6651489B2 (ja) ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US20200360294A1 (en) Nanoparticle Compositions and Methods for Synthesis Thereof
TWI293884B (en) Improved water-insoluble drug particle process
CN104188909A (zh) 用于制备商品化纳米颗粒和微粒粉末的方法
CN106420667A (zh) 双氯芬酸的新剂型
CN102438600A (zh) 用于改善生物活性物质溶出度特征的方法
CN102740835A (zh) 包封的纳米颗粒在工业规模的制备
RU2684914C2 (ru) Препараты метаксалона
AU2016203251B2 (en) Methods for the Preparation of Biologically Active Compounds in Nanoparticle Form
AU2013273795B2 (en) Method for the Preparation of Biologically Active Compounds in Nanoparticle Form
AU2012203877B2 (en) Methods For The Preparation Of Biologically Active Compounds In Nanoparticulate Form

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20091028